US FDA Mulls ‘Orange Book’ Listing For Device, REMS, Digital App Patents
Executive Summary
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
You may also be interested in...
Possible Orange Book Revisions Back In Play With US FDA Report To Congress
Agency is setting up an internal working group to assess whether certain patent information should be included or removed from the Orange Book. PhRMA, AAM and others address therapeutic equivalence ratings and listing of device-related and REMS-related patents.
Possible Orange Book Revisions Back In Play With US FDA Report To Congress
Agency is setting up an internal working group to assess whether certain patent information should be included or removed from the Orange Book. PhRMA, AAM and others address therapeutic equivalence ratings and listing of device-related and REMS-related patents.
FDA Airs ‘Concerns’ Over IP Barriers
Senators press for sharing of FDA applications with PTO as Woodcock letter seeks collaboration on everything from PTAB to patent term extensions to ‘possible misuse of the patent system.’